SteadyMed, Cardiome partner to commercialize PAH drug Trevyent outside US
Trevyent is SteadyMed’s lead drug product candidate currently under development stage that combines its PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat PAH. As part of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.